We all experienced the importance of at-home testing from the Covid19 pandemic and today's guest is helping bring rapid, affordable, and accurate tests to everyone including traditionally underserved areas.  Dive into how Domus Diagnostics got started, the importance of Nucleic Acid Testing, and getting started with clinical trials to get FDA clearance with Kelly and Paul on this episode of From Lab to Launch.About Paul ChapmanFrom sales representative to CEO, Board Member and Angel Investor, Paul Chapman has over 25 years of international business leadership experience in Molecular Diagnostics, Point of Care Diagnostics, Medical Devices and Life Sciences. He is skilled at change agent and is a creative, action-oriented leader with a broad base of international Diagnostic, Medical Device and Life Sciences executive experience.  Whether creating a new business or optimizing existing business models, Paul has created significant value by focusing on development of a high-performance culture through professional "A+" teams that he helps build.About Domus DiagnosticsDomus Diagnostics  seeks to create tests for infectious diseases that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises. All this not only in the US but in every global market including underserved areas - talk about a big vision! LinksDomus Diagnostics: https://www.domusdx.com/ Paul’s LinkedIn:  https://www.linkedin.com/in/paul-chapman-7b44508/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez